ipatasertib + atezolizumab + docetaxel

This is a **combination regimen** comprising three active agents: - **Ipatasertib** is a potent and selective pan-AKT inhibitor (small molecule), targeting the AKT pathway involved in cell survival, proliferation, and therapy resistance in cancer[4][5]. - **Atezolizumab** is a monoclonal antibody immune checkpoint inhibitor targeting Programmed Death-Ligand 1 (PD-L1), intended to activate anti-tumor immune responses[5]. - **Docetaxel** is a taxane-class cytotoxic anti-neoplastic agent inhibiting microtubule depolymerization, resulting in cell cycle arrest and apoptosis[1]. This combination has been investigated in Phase 1 trials for **metastatic castration-resistant prostate cancer (mCRPC),** as well as advanced breast cancer (notably triple-negative breast cancer, TNBC), where it seeks to leverage synergy between targeted AKT inhibition, immune checkpoint blockade, and cytotoxic chemotherapy[1][5]. The development status for prostate cancer is terminated[1]; there is no evidence of ongoing late-phase trials for breast cancer specifically with docetaxel in combination with ipatasertib and atezolizumab, though related taxanes (paclitaxel, nab-paclitaxel) have been studied extensively[5].

Brand names

atezolizumab (Tecentriq)docetaxel (Taxotere)

Other names

ipatasertib + atezolizumab + docetaxel